empty
 
 
bg
Търсене
Подкрепа
Незабавно отваряне на акаунт
Платформа за търговия
Депозит / Теглене
Търсене
За начинаещи За търговци За партньори Вземете си почивка За ИнстаФорекс
bg
#BGNE Обратно към списъка с инструменти #BMY

Конвентор на валута

Biogen Inc.
197.74 USD
10 Jun 2026 15:47
Ценова промяна (% chg)
$0
(0%)
Предишно затваряне
Предишно затваряне

Затваряща цена, предишен ден.
$197.74
Отваряне
Отваряне

Цена на отваряне.
$192.56
Дневен връх
Дневен връх

Най-високата цена през последния търговски ден.
$197.74
Дневно дъно
Дневно дъно

Най-ниската цена през последния ден за търговия
$197.74
52-седмичен връх
52-седмичен връх

Връх на ценовия диапазон за последните 52 седмици
$197.74
52-седмично дъно
52-седмично дъно

Дъно на ценовия диапазон за последните 52 седмици
$184.66
Свалете архива
Buy
197.74
Sell
197.74
Open the chart in full screen view
Buy
197.74
Sell
197.74
Свалете архива
Open the chart in full screen view

Biogen Inc. About company

Biogen Inc. is an American biopharmaceutical company founded in 1978. Initially, the company was headquartered in Switzerland, with all studies being conducted in European countries. Later, most of the company’s research centers were moved to the United States.

Biogen Inc. is engaged in the production of drugs based on DNA studies. At present, the company produces drugs used to treat multiple sclerosis, SMA, Alzheimer's disease, and other disorders.

Biogen’s market cap is $38.33 billion. Last year, its annual revenue stood at $10.981 billion, with net income at $1.556 billion.

Biogen’s shares and factors affecting their value

Its stock has been listed on the NASDAQ exchange under the ticker BIIB since 1983. The initial share price was $23.

Today, the company's shares are worth $257-$267. Over the past year, their value has ranged from $187 to $291.

When trading Biogen’s stock, traders are recommended to keep track of:

  • The products manufactured by the drugmaker are in demand. Moreover, their relevance is bound to increase in the future due to the world's aging population as well as progressive diseases among the elderly;
  • If the company passes clinical trials and receives a patent for a drug, it provides itself with an opportunity to make profits for at least 12 years, while other companies are prohibited from releasing analogues;
  • If Aducanumab receives approval as a treatment for Alzheimer's disease, the company’s capitalization will increase several times;
  • The company has good prospects in the market as it is greatly underestimated in comparison to competitors.

Не можете да говорите точно сега?
Задайте въпроса си в чат.